COHANCE

Cohance Lifesciences Balance Sheet

₹454.40-0.57%
Market cap
₹17,384 crore
P/E
163.6
P/B
4.44
ROE
4.7%
Dividend yield
1.20%

As of Mar 2022, Cohance Lifesciences had total assets of ₹13,700 crore and borrowings of ₹1,200 crore, against shareholders' equity of ₹9,000 crore — a debt-to-equity ratio of 0.13. Borrowings rose 1,606.00% from Mar 2023.

Cohance Lifesciences balance sheet

As at each financial year end, newest first. H1 = half-year.

Cohance Lifesciences balance sheet (₹ crore)
ItemMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital50025.4625.4625.4638.26
Reserves8,5001,4651,7652,0842,267
Borrowings1,20070.3465.01486400
Other liabilities3,5001601391,2021,295
Total liabilities13,7001,9662,2555,4815,730
Fixed assets6,5007697882,1032,170
Capital work in progress400100100100100
Investments2,5000.074511,0961,146
Other assets4,3005906761,6441,719
Total assets13,7001,9662,2555,4815,730

Balance sheet ratios

Debt to equity
0.13

Source: Company filings (consolidated), in ₹ crore. Data as of 7 October 2026. How this data is compiled.

Cohance Lifesciences balance sheet — frequently asked questions

What is the total debt of Cohance Lifesciences?

Cohance Lifesciences reported borrowings of ₹1,200 crore as of Mar 2022, compared with ₹70.34 crore as of Mar 2023.

What is Cohance Lifesciences' debt-to-equity ratio?

Based on the Mar 2022 balance sheet, Cohance Lifesciences' debt-to-equity ratio is 0.13 — borrowings of ₹1,200 crore against equity capital and reserves of ₹9,000 crore.

What are Cohance Lifesciences' total assets?

Cohance Lifesciences' total assets were ₹13,700 crore as of Mar 2022, including fixed assets of ₹6,500 crore and investments of ₹2,500 crore.

Same Data For Peers

Trade Cohance Lifesciences With ATS

Track COHANCE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.

Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.